Developing drugs in cancer-related bone pain

Maurizio Lucchesi, Gaetano Lanzetta, Andrea Antonuzzo, Antonio Rozzi, Iacopo Sardi, Claudio Favre, Carla Ida Ripamonti, Daniele Santini, Grazia Armento

Research output: Contribution to journalReview articlepeer-review


INTRODUCTION: Cancer-related bone pain is a frequent and important key problem for metastatic patients that may reduce quality of life, with related limitations in daily activities and morbidity. Often traditional approach to pain may fail given the complex pathophysiology of this phenomenon.

METHODS: The aim of this review is to describe promising therapies for cancer-related bone pain, from the pathophysiology to the clinical trials currently ongoing. Moreover, any new evidence for better approach to cancer-related bone pain with the traditional drugs is also considered.

CONCLUSIONS: In clinical practice opioids remain the most important pharmacologic treatment for severe pain related to bone cancer. Regard developing drugs, anti-NGF and anti-TrkA are the most investigated new drug in this setting, but a future role in clinical practice is still uncertain.

Original languageEnglish
Pages (from-to)66-74
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - Nov 2017


  • Journal Article
  • Review


Dive into the research topics of 'Developing drugs in cancer-related bone pain'. Together they form a unique fingerprint.

Cite this